1 Lotronex ® (alosetron HCl) Tablets Risk-Benefit Issues Victor F. C. Raczkowski, M.D. Director, Division of Gastrointestinal and Coagulation Drug Products.
leziuni veziculo-buloase
PATHOPHYSIOLOGY Mental Illness and Cognitive Disorders Project Mrs. Bowman Student Name: Nemmer R. Miari April 7 th, 2015.
Systemic Lupus Erythematosus. Intended Learning Objectives (ILOs) Identify definition and causes of SLE.Identify definition and causes of SLE. Understand.
DR: DRGEHAN MOHAMED DR. GEHAN MOHAMED Systemic Lupus Erythermatosus(SLE)
Essentials of the Pediatric Exam. Essentials of the Pediatric Exam Interviewing Interviews occur in different clinical settings –hospital admission –outpatient.
1 How to use irrelevant plasma and urine drug concentration in doping control in the FEI. PL Toutain UMR 181 Physiopathologie et Toxicologie Expérimentales;
Logistic Regression: Part 2 “Why include covariate adjustment?” Confounding, Mediation and Attenuation Robert Boudreau, PhD Co-Director of Methodology.
CLINICAL MEDICINE EXCRETORY SYSTEM Diseases & Disorders.
Pharmaceutical chemistry Hit to lead. Chemistry in R&D Exploratory development Full development IDEAIDEA DrugDrug CANDIDATE POCTARGET Therapeutic research.
Housing Families with Substance Use Challenges
Housing Families with Substance Use Challenges July 18, 2006 Deborah Werner Children and Family Futures 4940 Irvine Blvd., Ste 202 * Irvine, CA 92620 714.505.3525.